Anemia in chronic heart failure: Can we treat? What to treat?

Stephan Von Haehling, Markus S. Anker, Ewa A. Jankowska, Piotr Ponikowski, Stefan D. Anker

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Even though anemia is a significant comorbidity regularly observed in patients with chronic heart failure (HF), only in recent years systematic therapeutic research has been started. This article aims to review the aspects of anemia in chronic HF that are relevant for making treatment decisions, beginning with the definition of anemia and its incidence and prevalence of anemia in patients with chronic HF. Considering the etiology and prognostic impact of anemia in chronic HF, several treatment options will be considered. The latter are the application of erythropoiesis-stimulating agents (erythropoietin or darbepoetin alfa) or in the application of intravenous iron (e.g., iron carboxymaltose). According to the results seen in the FAIR-HF trial, iron supplementation should be particularly considered to improve symptoms and quality of life. Intravenous iron application may result in higher compliance and much faster treatment response than oral iron. The RED-HF study will show whether use of darbepoetin alfa in anemic patients with chronic HF will reduce the combined endpoint of death for any reason or hospitalization for heart failure.

Original languageEnglish
Pages (from-to)203-210
Number of pages8
JournalHeart Failure Reviews
Volume17
Issue number2
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Anemia
Heart Failure
Iron
Hematinics
Therapeutic Human Experimentation
Erythropoietin
Compliance
Comorbidity
Decision Making
Hospitalization
Therapeutics
Quality of Life
Incidence

Keywords

  • Anemia
  • Erythropoietin
  • Heart failure
  • Intravenous iron
  • Outcome
  • Symptoms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Von Haehling, S., Anker, M. S., Jankowska, E. A., Ponikowski, P., & Anker, S. D. (2012). Anemia in chronic heart failure: Can we treat? What to treat? Heart Failure Reviews, 17(2), 203-210. https://doi.org/10.1007/s10741-011-9283-x

Anemia in chronic heart failure : Can we treat? What to treat? / Von Haehling, Stephan; Anker, Markus S.; Jankowska, Ewa A.; Ponikowski, Piotr; Anker, Stefan D.

In: Heart Failure Reviews, Vol. 17, No. 2, 03.2012, p. 203-210.

Research output: Contribution to journalArticle

Von Haehling, S, Anker, MS, Jankowska, EA, Ponikowski, P & Anker, SD 2012, 'Anemia in chronic heart failure: Can we treat? What to treat?', Heart Failure Reviews, vol. 17, no. 2, pp. 203-210. https://doi.org/10.1007/s10741-011-9283-x
Von Haehling S, Anker MS, Jankowska EA, Ponikowski P, Anker SD. Anemia in chronic heart failure: Can we treat? What to treat? Heart Failure Reviews. 2012 Mar;17(2):203-210. https://doi.org/10.1007/s10741-011-9283-x
Von Haehling, Stephan ; Anker, Markus S. ; Jankowska, Ewa A. ; Ponikowski, Piotr ; Anker, Stefan D. / Anemia in chronic heart failure : Can we treat? What to treat?. In: Heart Failure Reviews. 2012 ; Vol. 17, No. 2. pp. 203-210.
@article{d448d912c09b4ee09c6daa1f6e1b731f,
title = "Anemia in chronic heart failure: Can we treat? What to treat?",
abstract = "Even though anemia is a significant comorbidity regularly observed in patients with chronic heart failure (HF), only in recent years systematic therapeutic research has been started. This article aims to review the aspects of anemia in chronic HF that are relevant for making treatment decisions, beginning with the definition of anemia and its incidence and prevalence of anemia in patients with chronic HF. Considering the etiology and prognostic impact of anemia in chronic HF, several treatment options will be considered. The latter are the application of erythropoiesis-stimulating agents (erythropoietin or darbepoetin alfa) or in the application of intravenous iron (e.g., iron carboxymaltose). According to the results seen in the FAIR-HF trial, iron supplementation should be particularly considered to improve symptoms and quality of life. Intravenous iron application may result in higher compliance and much faster treatment response than oral iron. The RED-HF study will show whether use of darbepoetin alfa in anemic patients with chronic HF will reduce the combined endpoint of death for any reason or hospitalization for heart failure.",
keywords = "Anemia, Erythropoietin, Heart failure, Intravenous iron, Outcome, Symptoms",
author = "{Von Haehling}, Stephan and Anker, {Markus S.} and Jankowska, {Ewa A.} and Piotr Ponikowski and Anker, {Stefan D.}",
year = "2012",
month = "3",
doi = "10.1007/s10741-011-9283-x",
language = "English",
volume = "17",
pages = "203--210",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Anemia in chronic heart failure

T2 - Can we treat? What to treat?

AU - Von Haehling, Stephan

AU - Anker, Markus S.

AU - Jankowska, Ewa A.

AU - Ponikowski, Piotr

AU - Anker, Stefan D.

PY - 2012/3

Y1 - 2012/3

N2 - Even though anemia is a significant comorbidity regularly observed in patients with chronic heart failure (HF), only in recent years systematic therapeutic research has been started. This article aims to review the aspects of anemia in chronic HF that are relevant for making treatment decisions, beginning with the definition of anemia and its incidence and prevalence of anemia in patients with chronic HF. Considering the etiology and prognostic impact of anemia in chronic HF, several treatment options will be considered. The latter are the application of erythropoiesis-stimulating agents (erythropoietin or darbepoetin alfa) or in the application of intravenous iron (e.g., iron carboxymaltose). According to the results seen in the FAIR-HF trial, iron supplementation should be particularly considered to improve symptoms and quality of life. Intravenous iron application may result in higher compliance and much faster treatment response than oral iron. The RED-HF study will show whether use of darbepoetin alfa in anemic patients with chronic HF will reduce the combined endpoint of death for any reason or hospitalization for heart failure.

AB - Even though anemia is a significant comorbidity regularly observed in patients with chronic heart failure (HF), only in recent years systematic therapeutic research has been started. This article aims to review the aspects of anemia in chronic HF that are relevant for making treatment decisions, beginning with the definition of anemia and its incidence and prevalence of anemia in patients with chronic HF. Considering the etiology and prognostic impact of anemia in chronic HF, several treatment options will be considered. The latter are the application of erythropoiesis-stimulating agents (erythropoietin or darbepoetin alfa) or in the application of intravenous iron (e.g., iron carboxymaltose). According to the results seen in the FAIR-HF trial, iron supplementation should be particularly considered to improve symptoms and quality of life. Intravenous iron application may result in higher compliance and much faster treatment response than oral iron. The RED-HF study will show whether use of darbepoetin alfa in anemic patients with chronic HF will reduce the combined endpoint of death for any reason or hospitalization for heart failure.

KW - Anemia

KW - Erythropoietin

KW - Heart failure

KW - Intravenous iron

KW - Outcome

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=84862578773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862578773&partnerID=8YFLogxK

U2 - 10.1007/s10741-011-9283-x

DO - 10.1007/s10741-011-9283-x

M3 - Article

C2 - 21979835

AN - SCOPUS:84862578773

VL - 17

SP - 203

EP - 210

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 2

ER -